Signature-driven repurposing of Midostaurin for combination with MEK1/2 and KRASG12C inhibitors in lung cancer

Drug combinations are key to circumvent resistance mechanisms compromising response to single anti-cancer targeted therapies. The implementation of combinatorial approaches involving MEK1/2 or KRASG12C inhibitors in the context of KRAS-mutated lung cancers focuses fundamentally on targeting KRAS pro...

Descripción completa

Detalles Bibliográficos
Autores principales: Macaya, Irati, Roman, Marta, Welch, Connor, Entrialgo-Cadierno, Rodrigo, Salmon, Marina, Santos, Alba, Feliu, Iker, Kovalski, Joanna, Lopez, Ines, Rodriguez-Remirez, Maria, Palomino-Echeverria, Sara, Lonfgren, Shane M., Ferrero, Macarena, Calabuig, Silvia, Ludwig, Iziar A., Lara-Astiaso, David, Jantus-Lewintre, Eloisa, Guruceaga, Elizabeth, Narayanan, Shruthi, Ponz-Sarvise, Mariano, Pineda-Lucena, Antonio, Lecanda, Fernando, Ruggero, Davide, Khatri, Purvesh, Santamaria, Enrique, Fernandez-Irigoyen, Joaquin, Ferrer, Irene, Paz-Ares, Luis, Drosten, Matthias, Barbacid, Mariano, Gil-Bazo, Ignacio, Vicent, Silve
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10564741/
https://www.ncbi.nlm.nih.gov/pubmed/37816716
http://dx.doi.org/10.1038/s41467-023-41828-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10564741/
https://www.ncbi.nlm.nih.gov/pubmed/37816716
http://dx.doi.org/10.1038/s41467-023-41828-z

Ejemplares similares